Abstract
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses nivolumab (Opdivo); strength: 40 mg nivolumab/4 mL (10 mg/mL) and 100 mg nivolumab/10 mL (10 mg/mL); route of administration: IV infusion. Indication: Opdivo, as monotherapy, is indicated for the adjuvant treatment of adult patients with stage IIB or IIC melanoma following complete resection.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
